Physician profile
Kris C Kealey
NPI 1144243361
$3,417.33
in general payments reported to CMS, 2019-2025
24 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.11 · 2021: $338 · 2022: $775 · 2023: $549 · 2024: $1,269 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $627.65 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $538.17 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $460.43 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $347.24 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $247.80 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $150.78 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $140.85 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $137.62 | 2021 | |
| Pfizer INC. | $131.12 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $94.28 | 2022 | |
| Merck Sharp & Dohme LLC | $80.33 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $72.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $70.94 | 2022 | |
| Viiv Healthcare Company | $55.19 | 2024 | Apretude |
| Lexicon Pharmaceuticals, INC. | $52.03 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $33.69 | 2021 | |
| Corcept Therapeutics | $28.97 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $26.42 | 2023 | |
| Esperion Therapeutics, INC. | $24.99 | 2024 | Nexletol |
| Hologic Sales and Service, LLC | $23.18 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.64 | 2024 | Evkeeza |
| Astellas Pharma US INC | $19.34 | 2022 | |
| Gilead Sciences, INC. | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Kealey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.